Berman Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Berman Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$4K	Sell	476 -10	-2%	-$94	﹤0.01%	1512
2021 Q2	$4K	Hold	486	–	–	﹤0.01%	1427
2021 Q1	$5K	Sell	486 -135	-22%	-$1.55K	﹤0.01%	1292
2020 Q4	$5K	Buy	621 +175	+39%	+$1.68K	﹤0.01%	1175
2020 Q3	$4K	Sell	446 -22	-5%	-$233	﹤0.01%	1141
2020 Q2	$5K	Sell	468 -1,321	-74%	-$14.9K	﹤0.01%	998
2020 Q1	$15K	Buy	1,789 +1,427	+394%	+$14.6K	﹤0.01%	570
2019 Q4	$3K	Sell	362 -45	-11%	-$402	﹤0.01%	1135
2019 Q3	$2K	Buy	407 +362	+804%	+$2.77K	﹤0.01%	1232
2019 Q2	$0	Sell	45 -39	-46%	-$470	﹤0.01%	1569
2019 Q1	$1K	Sell	84 -11	-12%	-$194	﹤0.01%	1266
2018 Q4	$1K	Buy	+95	New	+$1.95K	﹤0.01%	1065

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Berman Capital Advisors's TEVA Position: Q3 2021 in Review

Berman Capital Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 2.1% in Q3 2021, selling an estimated $94 and leaving 476 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1512.

Berman Capital Advisors first reported a position in TEVA in Q4 2018 and has held it in 12 quarters since. The position peaked at $15K in Q1 2020. 429 funds tracked by Wall St. Rank hold TEVA as of Q3 2021.

Berman Capital Advisors held 476 shares of Teva Pharmaceuticals worth $4K as of Q3 2021.
Berman Capital Advisors sold 10 Teva Pharmaceuticals shares in Q3 2021, an estimated $94.
Teva Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1512 holding.
Berman Capital Advisors first reported a position in Teva Pharmaceuticals in Q4 2018 and has held it in 12 quarters since.
Berman Capital Advisors's Teva Pharmaceuticals position peaked at $15K in Q1 2020.
429 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.